Does SummaCare Cover Forteo (Teriparatide)? A Complete Insurance and Clinical Guide

What Is Forteo and Why Does It Require Special Coverage Review?

Forteo is a daily subcutaneous injection of recombinant human parathyroid hormone fragment teriparatide (1-34), approved by the FDA in 2002 for postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis at high fracture risk [1]. Unlike antiresorptive agents such as alendronate or zoledronic acid, teriparatide is an anabolic agent: it stimulates osteoblast activity and directly builds new bone matrix rather than simply slowing resorption [2].

Because of that mechanism and its high acquisition cost (retail price $3,200, $3,800 per 28-day pen), every major U.S. payer, including SummaCare, places Forteo on a specialty tier with a mandatory prior authorization (PA) process. The FDA label limits lifetime use to 24 months based on osteosarcoma findings in Fischer 344 rats at suprapharmacologic doses, a risk not demonstrated in humans at clinical doses but sufficient to justify regulatory caution [1].

The key fracture trial, published in the New England Journal of Medicine, enrolled 1,637 postmenopausal women with prior vertebral fractures [3]. After a median of 21 months, teriparatide 20 mcg/day reduced new vertebral fracture risk by 65% (relative risk 0.35; 95% CI 0.22, 0.55; P<0.001) and nonvertebral fragility fractures by 53% compared with placebo. That level of efficacy explains why clinicians pursue coverage aggressively when antiresorptives have failed. The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines recommend anabolic therapy as first-line in patients at "very high" fracture risk, defined as a T-score below -3.0, multiple vertebral fractures, or prior hip fracture [4].

How SummaCare Structures Its Pharmacy Benefit for Forteo

SummaCare is a regional managed-care plan based in Akron, Ohio, offering commercial HMO/PPO products and Medicare Advantage plans to employers and individuals primarily in Summit, Cuyahoga, and surrounding Northeast Ohio counties. Its formulary follows a five-tier structure for most commercial plans:

• Tier 1: preferred generics
• Tier 2: non-preferred generics
• Tier 3: preferred brand
• Tier 4: non-preferred brand / specialty
• Tier 5: select specialty injectables (plan-dependent)

Forteo sits at Tier 4 or Tier 5 depending on the specific SummaCare product year. Cost-sharing at these tiers ranges from approximately $70, $150 per fill on commercial plans before any manufacturer savings card is applied. Under SummaCare Medicare Advantage plans, Forteo is typically covered under Part D with formulary placement at the specialty tier, where cost-sharing is calculated as a percentage of the drug's negotiated price rather than a flat copay.

The National Osteoporosis Foundation estimates that direct annual costs of osteoporotic fractures in the United States exceed $57 billion, a figure that continues climbing as the population ages [5]. Payers including SummaCare therefore conduct rigorous utilization management to ensure Forteo is prescribed to patients whose fracture risk genuinely justifies the cost, not as a first-line agent when cheaper alternatives remain untried.

Prior Authorization Criteria SummaCare Typically Applies

SummaCare's PA criteria for Forteo follow the general framework used by most commercial payers and align with AACE and Endocrine Society guidelines [4][6]. The prescribing clinician must document all of the following:

Diagnosis confirmation. The patient must carry an ICD-10 diagnosis of osteoporosis (M81.0 for postmenopausal, M81.8 for age-related, or M80.x for osteoporosis with current fracture). A dual-energy X-ray absorptiometry (DXA) scan showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip satisfies this criterion [6]. Patients with a T-score between -1.0 and -2.5 may qualify if a documented fragility fracture (hip or vertebral) is on record.

Step-therapy requirement. SummaCare generally requires a trial of at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly are the most common) at adequate doses for a minimum of 6 to 12 months, with documented intolerance or inadequate response [7]. Inadequate response may be defined as a new fracture despite therapy or continued bone mineral density loss of more than 5% over two years on DXA.

Prescriber specialty. PA requests submitted by endocrinologists, rheumatologists, or orthopedic surgeons with documented osteoporosis management experience receive faster approval. Some SummaCare PA reviewers accept primary care physician requests when specialist consultation is noted in the chart.

Duration and renewal. Initial approval covers 6 months. Renewal requests every 6 months are required up to the 24-month lifetime maximum, with each renewal requiring documentation that the patient remains on therapy and is tolerating injections.

The 2022 American College of Rheumatology (ACR) guideline for glucocorticoid-induced osteoporosis conditionally recommends teriparatide over bisphosphonates for patients taking more than 7.5 mg/day of prednisone-equivalent for longer than 3 months who are at very high fracture risk [8]. Submitting this guideline language with the PA request strengthens the case when glucocorticoid use is the indication.

Step-by-Step: How to Submit a Forteo PA to SummaCare

Getting a PA approved requires organized, complete documentation submitted on the first attempt. Incomplete submissions are the leading cause of initial denial.

Step 1. Obtain the correct PA form. SummaCare uses CoverMyMeds and its own provider portal for specialty PA submissions. The form for injectable osteoporosis agents typically requests DXA results, fracture history, prior therapy names and dates, and ICD-10 codes.

Step 2. Attach clinical documentation. Include the DXA report (T-score numeric values, not just the narrative impression), the most recent office note, the bisphosphonate trial duration with dates, and the reason for switching (intolerance or clinical failure). A bone turnover marker result, such as serum CTX (C-terminal telopeptide) or P1NP, adds objective evidence of disease severity; AACE recommends P1NP monitoring during anabolic therapy to confirm response [4].

Step 3. Reference guidelines. A brief cover letter from the prescriber citing the AACE 2020 guideline recommendation for anabolic therapy at very high fracture risk and the NEJM fracture reduction data can shorten review time. Peer-to-peer calls with the SummaCare medical director are available and often resolve borderline cases within 48 hours.

Step 4. Track the timeline. Under Ohio insurance law and federal rules, standard PA decisions must be issued within 3 business days; urgent requests within 24 to 72 hours. SummaCare is required to provide written notice of denial with the specific clinical rationale.

What to Do if SummaCare Denies Forteo Coverage

An initial denial is not the end of the road. Approximately 30 to 40% of specialty drug PA appeals are overturned on first-level review when complete clinical documentation is submitted, based on data from health plan appeal audits compiled by the Journal of Managed Care and Specialty Pharmacy [9].

Level 1 internal appeal. File within 30 days of the denial notice. Attach any additional clinical documentation: updated DXA results, fracture imaging reports, bone turnover markers, or a letter of medical necessity signed by the treating physician. If the denial cites "no prior bisphosphonate trial," document every contraindication to bisphosphonates: esophageal dysmotility, renal impairment (eGFR <35 mL/min/1.73 m², a recognized contraindication per FDA labeling for oral bisphosphonates), or documented GI adverse events with pharmacy records [10].

Level 2 external independent review. Ohio law requires insurers to offer an external review by an independent review organization (IRO) if the internal appeal fails. The IRO decision is binding on SummaCare. Submit the same clinical package plus published guidelines; IRO reviewers often weight AACE and ACR guideline citations heavily.

Expedited appeal for urgent cases. If the patient has had a recent hip or vertebral fracture, file for an expedited review. SummaCare must respond within 72 hours. Attach the fracture imaging report and the hospital or ED visit documentation.

The HealthRX clinical team has developed an internal checklist for Forteo PA submissions that reduces first-attempt denial rates in our patient cohort. The checklist covers seven documentation domains: DXA numeric values, fracture history with imaging dates, bisphosphonate trial dates and doses, intolerance or failure rationale, bone turnover marker values, prescriber specialty notation, and the specific guideline citation matching the patient's indication. Patients whose submissions include all seven domains receive approval on the first attempt at materially higher rates than those with incomplete packages.

Cost and Patient Assistance Options When SummaCare Coverage Falls Short

Even with coverage, Tier 4 cost-sharing on Forteo can be burdensome. Several programs reduce or eliminate out-of-pocket cost.

Lilly Cares Foundation. Eli Lilly operates a patient assistance program for uninsured or underinsured patients. Income eligibility thresholds change annually; patients at or below 400% of the federal poverty level may receive Forteo at no charge. Applications are submitted at lillycares.com or through the prescriber's office.

Lilly Insulin Value Program savings card. For commercially insured patients (not Medicare), Lilly's savings card covers up to $850 per month of out-of-pocket cost per 28-day pen. This card cannot be used with any federal health care program including Medicare Part D or Medicaid.

Medicare Low-Income Subsidy (LIS / Extra Help). SummaCare Medicare Advantage members who qualify for the Part D Low-Income Subsidy pay a maximum of $11.20 per month (2024 standard benchmark) for covered specialty drugs. LIS eligibility is determined by the Social Security Administration based on income and asset thresholds [11].

340B pricing. Patients receiving care at federally qualified health centers (FQHCs) or qualifying hospital outpatient departments enrolled in the 340B Drug Pricing Program may access Forteo at substantially reduced acquisition cost, which the facility can pass through to the patient. Availability varies by institution.

Biosimilar consideration. The FDA approved teriparatide biosimilars including Bonsity (Alvogen) and Tlando... actually, Bonsity (teriparatide injection; Alvogen, approved 2021) and Tymlos (abaloparatide; Radius Health) is a related but distinct anabolic agent, not a biosimilar. Bonsity is a true biosimilar to Forteo and is often placed on a lower specialty tier by payers, with SummaCare increasingly preferring it over reference Forteo for new starts [12]. If cost is a barrier, asking the prescriber about Bonsity may be a practical alternative with the same 20 mcg/day dosing and the same FDA-approved indications.

Clinical Context: Who Actually Needs Forteo and Who Can Use Cheaper Options

Not every patient with osteoporosis needs teriparatide, and SummaCare's step-therapy requirement reflects legitimate clinical reasoning. Oral bisphosphonates remain the first-line standard of care for most patients with osteoporosis, supported by decades of fracture data and generic pricing of less than $10 per month [7].

Alendronate 70 mg once weekly reduced vertebral fracture risk by 47% (RR 0.53; 95% CI 0.41, 0.68) in the FIT trial (N=2,027) after three years, with a cost that is orders of magnitude below Forteo [13]. Zoledronic acid 5 mg IV annually reduced hip fracture risk by 41% and vertebral fracture risk by 70% in the HORIZON-Key Fracture Trial (N=7,736) [14]. These agents are appropriate for the majority of patients with T-scores between -2.5 and -3.0 without prior fracture.

Teriparatide offers meaningful advantages in specific populations: patients who have already fractured on a bisphosphonate, those with very low T-scores (below -3.0), those on chronic glucocorticoids at high fracture risk, and those with documented bisphosphonate intolerance. In these groups, the anabolic mechanism produces bone formation that antiresorptives cannot replicate. A 12-month head-to-head trial (VERO, N=680) found teriparatide reduced new vertebral fractures by 56% compared with risedronate (P<0.001), confirming superiority over an active comparator, not just placebo [15].

For patients switching from a bisphosphonate to teriparatide, the sequence matters. Patients on long-term bisphosphonate therapy may have a blunted anabolic response to teriparatide due to suppressed bone turnover; AACE recommends considering baseline P1NP measurement and monitoring at 3 months to confirm the expected anabolic response (P1NP rise of 60 to 120 mcg/L or greater) [4].

SummaCare Medicare Advantage vs. Commercial Plan Coverage Differences

SummaCare offers both commercial products and Medicare Advantage (MA) plans in Northeast Ohio. The coverage rules for Forteo differ materially between the two.

Under commercial SummaCare, Forteo is a pharmacy benefit at Tier 4, subject to the PA criteria above, with manufacturer savings card eligibility. Annual out-of-pocket maximums cap total cost-sharing once met.

Under SummaCare Medicare Advantage (Part D), Forteo is covered under the prescription drug benefit using the plan's Medicare formulary. Medicare Part D plans are prohibited from accepting manufacturer savings cards, so the Lilly card cannot reduce cost-sharing for MA members. The standard Medicare Part D coverage phases (deductible, initial coverage, catastrophic) apply. In 2025, the Inflation Reduction Act changes cap Medicare Part D out-of-pocket spending at $2,000 annually, which meaningfully reduces total cost for high-cost drugs like Forteo [11].

Patients enrolled in a SummaCare Medicare Advantage plan who cannot afford Forteo cost-sharing should ask their plan about the Extra Help / LIS program and should inquire whether Bonsity (the teriparatide biosimilar) carries lower cost-sharing on the MA formulary.

Monitoring Requirements During Forteo Therapy That Support Ongoing PA Renewals

SummaCare renewal PAs require evidence of ongoing therapy and clinical monitoring. Clinicians should document at every renewal submission:

DXA scanning every 12 to 24 months is standard per NOF guidelines, with a repeat scan at 12 months expected to show lumbar spine BMD increase of 5 to 10% in responders [5]. Serum calcium should be checked at baseline, 1 month, and periodically thereafter; mild hypercalcemia occurs in approximately 11% of patients on teriparatide in clinical trials [3]. Serum PTH and 24-hour urine calcium are checked if hypercalcemia persists. Alkaline phosphatase or P1NP measured at baseline and 3 months confirms anabolic response and provides objective data for renewal submissions [4].

Patients should also be counseled on injection technique, site rotation (thigh or abdomen), refrigeration requirements (2, 8°C), and the 28-day pen shelf life after first use. Adherence data from the DANCE observational study (N=5,893) showed that only 53% of patients completed the full 24-month course [16]. Incomplete therapy substantially reduces fracture benefit, making adherence counseling part of clinical management and, indirectly, a factor in demonstrating value to payers at renewal.

After completing 24 months of teriparatide, sequential antiresorptive therapy is mandatory to preserve the bone gained. AACE recommends transitioning to denosumab 60 mg every 6 months subcutaneously or zoledronic acid 5 mg IV annually after completing anabolic therapy [4]. Without sequential therapy, BMD returns toward baseline within 12 to 18 months.

Practical Next Steps for Patients Seeking SummaCare Forteo Coverage

Call SummaCare member services (the number is on the back of the insurance card) to confirm the current formulary tier and PA requirements for Forteo under the specific plan year, since formularies change on January 1 each year. Ask specifically whether Bonsity is on a lower tier. Confirm whether the prescribing physician is in-network for SummaCare PA submissions on specialty pharmacy orders.

Contact the prescribing physician's office at least 2 weeks before the anticipated start date to allow time for PA submission and potential peer-to-peer review. Bring the most recent DXA report, a complete list of prior osteoporosis medications with dates, and any fracture imaging reports to the appointment.

If cost remains a barrier after PA approval, the Lilly Cares Foundation at 1-800-545-6962 can assess eligibility for free drug, and HealthRX care coordinators can assist with documentation preparation for appeal submissions.

A DXA T-score at the femoral neck of -3.0 or below, combined with a prior vertebral fracture, places a patient in the very-high-risk category where AACE assigns the strongest recommendation for anabolic-first therapy [4].